Wasatch Advisors LP Lowers Stake in Artivion, Inc. $AORT

Wasatch Advisors LP reduced its stake in shares of Artivion, Inc. (NYSE:AORT) by 23.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,388 shares of the company’s stock after selling 48,055 shares during the quarter. Wasatch Advisors LP’s holdings in Artivion were worth $5,727,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC boosted its position in shares of Artivion by 578.4% in the 4th quarter. SG Americas Securities LLC now owns 39,030 shares of the company’s stock worth $1,780,000 after purchasing an additional 33,277 shares in the last quarter. Vanguard Group Inc. boosted its position in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after buying an additional 141,030 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Artivion by 338.2% in the third quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock worth $5,174,000 after acquiring an additional 94,312 shares during the period. Kennedy Capital Management LLC grew its position in Artivion by 19.0% during the 3rd quarter. Kennedy Capital Management LLC now owns 437,792 shares of the company’s stock worth $18,536,000 after purchasing an additional 70,030 shares during the period. Finally, UBS Group AG raised its position in Artivion by 37.0% during the fourth quarter. UBS Group AG now owns 279,675 shares of the company’s stock valued at $12,756,000 after acquiring an additional 75,606 shares in the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on AORT shares. Citizens Jmp cut their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Weiss Ratings downgraded Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 8th. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Stifel Nicolaus set a $45.00 price objective on Artivion in a research note on Monday, June 1st. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $36.00 target price on shares of Artivion in a report on Tuesday, June 16th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and an average target price of $44.17.

Insider Activity at Artivion

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by company insiders.

Artivion Stock Up 4.3%

Shares of NYSE:AORT opened at $23.62 on Friday. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25. The firm’s 50-day moving average is $26.00 and its two-hundred day moving average is $35.33. The firm has a market capitalization of $1.15 billion, a PE ratio of 98.44 and a beta of 1.26. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.